Causes: Cancer, Cancer Research, Health, Medical Disciplines Research
Mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer.
Results: Immunotherapy has begun to transform cancer treatment. Medicines that unleash the immune system have enabled many patients to live longer, healthier lives. Checkpoint blockade, CAR T cell therapy, and oncolytic virus therapy has received FDA approval to treat a variety of cancers, including lung, colorectal, bladder, skin, head and neck, and kidney cancers as well as melanoma, lymphoma, and leukemia. For many decades since its founding in 1953, the Cancer Research Institute was the only nonprofit organization to believe immunotherapy could one day save lives. That day has come, and it's just the beginning. Immunotherapy has potential to treat nearly all forms of cancer. With continued research, we can learn to increase the effectiveness of these treatments so that more and eventually all patients benefit. CRI is committed to funding the most promising research, wherever it's being done, to accelerate the pace of progress and save more lives sooner.
Target demographics: Under the leadership of our Scientific Advisory Council, which includes 4 Nobel Laureates and 26 members of the National Academy of Sciences, CRI funds academic research in immunology and tumor immunology at universities and health research centers around the world.
Direct beneficiaries per year: Approximately 300 scientists and clinicians in 18 countries
Geographic areas served: National, International
Programs: The CRI Irvington Postdoctoral Fellowship Program furthers career development and supports laboratory research for promising young scientists working under the mentorship of leading immunologists. The Anna-Maria Kellen Clinical Accelerator is a unique nonprofit-academia-industry partnership model designed to develop, organize, and de-risk clinical study of next-generation combination cancer immunotherapies. The Clinic and Laboratory Integration Program (CLIP) grants provide catalytic support for translational laboratory studies designed to answer new specific scientific questions that arise in the clinic, with special focus on improving immunotherapy for cancer patients. The Lloyd J. Old STAR Program (Scientists TAking Risks) provides grants of $1.25 million over 5 years to mid-career scientists. This long-term funding will not be tied to a specific research project, but rather provides a degree of flexibility and freedom for investigators to explore out-of-the-box and disruptive avenues of research. The CRI Technology Impact Award provides seed funding of up to $200,000 to be used over 12-24 months to address the gap between technology development and clinical application of cancer immunotherapies. CRI's Impact Grants support research projects and public education and awareness initiatives for which funds have been specifically raised.
Mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer.
Results: Immunotherapy has begun to transform cancer treatment. Medicines that unleash the immune system have enabled many patients to live longer, healthier lives. Checkpoint blockade, CAR T cell therapy, and oncolytic virus therapy has received FDA approval to treat a variety of cancers, including lung, colorectal, bladder, skin, head and neck, and kidney cancers as well as melanoma, lymphoma, and leukemia. For many decades since its founding in 1953, the Cancer Research Institute was the only nonprofit organization to believe immunotherapy could one day save lives. That day has come, and it's just the beginning. Immunotherapy has potential to treat nearly all forms of cancer. With continued research, we can learn to increase the effectiveness of these treatments so that more and eventually all patients benefit. CRI is committed to funding the most promising research, wherever it's being done, to accelerate the pace of progress and save more lives sooner.
Target demographics: Under the leadership of our Scientific Advisory Council, which includes 4 Nobel Laureates and 26 members of the National Academy of Sciences, CRI funds academic research in immunology and tumor immunology at universities and health research centers around the world.
Direct beneficiaries per year: Approximately 300 scientists and clinicians in 18 countries
Geographic areas served: National, International
Programs: The CRI Irvington Postdoctoral Fellowship Program furthers career development and supports laboratory research for promising young scientists working under the mentorship of leading immunologists. The Anna-Maria Kellen Clinical Accelerator is a unique nonprofit-academia-industry partnership model designed to develop, organize, and de-risk clinical study of next-generation combination cancer immunotherapies. The Clinic and Laboratory Integration Program (CLIP) grants provide catalytic support for translational laboratory studies designed to answer new specific scientific questions that arise in the clinic, with special focus on improving immunotherapy for cancer patients. The Lloyd J. Old STAR Program (Scientists TAking Risks) provides grants of $1.25 million over 5 years to mid-career scientists. This long-term funding will not be tied to a specific research project, but rather provides a degree of flexibility and freedom for investigators to explore out-of-the-box and disruptive avenues of research. The CRI Technology Impact Award provides seed funding of up to $200,000 to be used over 12-24 months to address the gap between technology development and clinical application of cancer immunotherapies. CRI's Impact Grants support research projects and public education and awareness initiatives for which funds have been specifically raised.
info@cancerresearch.org
29 Broadway, Floor 4, New York, NY 10006
800-992-2623
Cancer
New York
